Role of pharmacogenetics in the use of CNS drugs: From drug pipeline to primary care?

Expert Review of Neurotherapeutics

Volumn 6, Issue 12, 2006, Pages 1765-1767

  Hopkins, Michael M ^a   Martin, Paul A ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; EMONAPRIDE; FLUOXETINE; HALOPERIDOL; PAROXETINE; SERTRALINE; VILAZODONE;

BRAIN FUNCTION; DEPRESSION; DRUG RESEARCH; EDITORIAL; FUNCTIONAL GENOMICS; GENETIC ANALYSIS; HUMAN; MEDICAL RESEARCH; NEUROSCIENCE; PHARMACOGENETICS; PRIMARY MEDICAL CARE;

CENTRAL NERVOUS SYSTEM AGENTS; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE;

EID: 33845911965     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.12.1765     Document Type: Editorial

References (15)

1. Dahl SG, Sylte I. From genomics to drug targets. J. Psychopharmacol. 20(Suppl. 4) 95-99 (2006).
2. Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nat. Rev. Genet. 5, 7-13 (2004).
3. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat. Rev. Genet. 937-947 (2004).
4. Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J. Psychopharmacol. 20(Suppl. 4), 85-94 (2006).
5. Kroeze WK, Roth BL. Screening the receptorome. J. Psychopharmacol. 20(Suppl. 4), 41-46 (2006).
6. Hopkins MM, Ibarreta D, Gaisser S et al. Putting pharmacogenetics into practice. Nat. Biotechnol. 24(4), 403-410 (2006).
7. Gurwitz D, Lunshof JE, Altman RB. A call for the creation of personalized medicine databases. Nat. Rev. Drug Discov. 23-26 (2006).
8. Kirchheiner J, Gründemann D, Schömig E. Contribution of allelic variations in transporters to the phenotype of drug response. J. Psychopharmacol. 20(Suppl. 4), 27-32 (2006).
9. Jarnagin K. ID and validation of biomarkers. Genetic Engineering News 6-7 (2006).
10. Lunshof JE, Pirohamed M, Gurwitz D. Personalized medicine: decades away? Pharmacogenomics 7(2), 237-241 (2006).
11. Kalorama Information. Molecular diagnostics for pharmacogenetic testing: testing volume, cost per test, and market potential www.kaloramainformation.com/
12. Martin PA, Lewis G, Smart A, Webster A. False positive? Prospects for the clinical and commercial development of pharmacogenetics. University of Nottingham/University of York www.nottingham.ac.uk/pgx
13. Institute for Prospective Technological Studies. Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. European Commission www.jrc.es/home/pages/detail.cfm?prs=1387
14. The Royal Society Personalised medicines: hopes and realities, London www.royalsoc.ac.uk/displaypagedoc.asp?id=15874
15. UK Pharmacogenetics Study Group. Policy issues in pharmacogenetics. www.york.ac.uk/res/pgx/publications